T-helper 2 (Th2) Cytokine Responses in Overweight/Obese Subjects
NCT02085759 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46
Last updated 2014-03-13
Summary
Cytokines are chemicals that are naturally made by your body. Certain cytokine levels are changed in the blood of patients who develop allergies and/or asthma. Cytokine levels may also be changed in some individuals who are overweight or obese. The purpose of this study is to determine if certain cytokine levels differ based on a person's weight and whether or not they have allergies or asthma. Information gathered in this study will be compared to information gathered from subjects who have participated in another similar study for patients who have allergies and/or asthma.
Conditions
Sponsors & Collaborators
-
Pennsylvania Allergy and Asthma Research Foundation
collaborator UNKNOWN -
West Penn Allegheny Health System
lead OTHER
Principal Investigators
-
David Skoner, MD · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
-
Deborah Gentile, MD · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2010-12-31
Countries
- United States
Study Locations
More Related Trials
-
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy
NCT02931955 ·Status: COMPLETED
-
Study to Asses Efficacy of Intralymphatic Immunotherapy
NCT01166269 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Tumor-specific T Cells in Lung Cancer
NCT02515760 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade
NCT04616235 ·Status: COMPLETED ·Phase: NA
-
Collection of Data and Samples From Healthy Donors for Use in Translational Research
NCT00090662 ·Status: RECRUITING
-
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03735589 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Therapy for Progressive and/or Refractory Hematologic Malignancies
NCT02223312 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Blood and Follicular Fluid Immune Cell Constitution in Patients Undergoing in Vitro Fertilization
NCT01083745 ·Status: UNKNOWN
-
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
NCT05238792 ·Status: RECRUITING ·Phase: PHASE1
-
Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine
NCT01290055 ·Status: COMPLETED ·Phase: PHASE4
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
NCT00879489 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
NCT05292859 ·Status: COMPLETED
-
T Cells Response to SARS COV 2 Peptides
NCT04573348 ·Status: UNKNOWN
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
NCT01235845 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients
NCT04990557 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus
NCT00001985 ·Status: COMPLETED
-
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
NCT00085436 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
NCT00625755 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
NCT03093350 ·Status: COMPLETED ·Phase: PHASE2
-
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00128622 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2